Organogenesis enters $75M at-the-market stock offering, shares fall 23%

What happened

Organogenesis Holdings Inc. (NASDAQ: ORGO) announced it entered an at-the-market (ATM) sales agreement with BTIG, LLC and Citizens JMP Securities, LLC on August 6, 2026. The agreement allows the wound-care and regenerative-medicine company to sell up to $75 million of its Class A common stock from time to time through the agents.

The company’s stock fell 22.82% to close at $1.86 on more than five times its average daily volume. The filing does not state why the company entered the agreement or how the proceeds will be used.

Details of the agreement

Under the ATM agreement, Organogenesis may sell shares into the Nasdaq Capital Market at prevailing market prices, subject to instructions it gives the agents (including price, time, or size limits). The agents receive a 3% commission on each share sold.

The shares are offered under a shelf registration statement (Form S-3) filed in August 2024 and declared effective that month. A prospectus supplement dated August 6, 2026 covers the ATM program. The company is not obligated to sell any shares under the agreement.

What this means

An ATM offering (or at-the-market offering) is a method for a publicly traded company to raise capital gradually by selling newly issued shares directly into the stock market at current prices, rather than through a traditional underwritten offering at a fixed discount. This gives the company flexibility to fund operations or investments without a single large dilutive event, though ongoing sales still dilute existing shareholders.

The filing is an 8-K under Item 1.01, which requires a company to disclose entering a material definitive agreement that is not made in the ordinary course of business. The agreement itself (filed as Exhibit 1.1) contains the full terms. The shelf registration statement (Form S-3) is a pre-registration that allows a company to offer securities over time; each type of offering requires a separate prospectus supplement.

Because the shares are sold at market prices, the company receives the sale proceeds less the 3% agent fee. The market reacted sharply downward on the news, possibly reflecting concern about future dilution, although the filing itself does not attribute the price move to any specific cause.